Latest news with #Jiangsu Hengrui Pharmaceuticals
Daily Mail
28-07-2025
- Business
- Daily Mail
GSK strikes £370m deal with Chinese rival Jiangsu Hengrui to develop up to a dozen new medicines
GSK has struck a £370million deal with a Chinese rival to develop up to a dozen medicines, including a promising candidate for a chronic lung condition. The deal with Jiangsu Hengrui Pharmaceuticals comes as GSK focuses on growing its pipeline to negate declining revenues from top drugs and vaccines amid slowing demand and rising competition. Under the deal, GSK will gain an exclusive licence to Hengrui's HRS-9821, which is being studied as a treatment for chronic obstructive pulmonary disease. GSK shares rose 0.4 per cent, or 5.5p, to 1398p.
Bloomberg
28-07-2025
- Business
- Bloomberg
Hengrui Shares Jump on GSK Deal Worth Up To $12 Billion
Jiangsu Hengrui Pharmaceuticals Co. shares rallied to their highest levels in four years after GSK Plc agreed to pay $500 million upfront for the company's potential chronic lung disease treatment. The firm's Shanghai-listed stock rose as much as 8.16% to reach its highest level since July 2021, while its Hong Kong-listed shares were up as much as 10.95% on Monday.
